Please use this identifier to cite or link to this item:
|Title:||Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.|
|Authors:||Seeman, Ego;Devogelaer, Jean-Pierre;Lorenc, Roman;Spector, Timothy;Brixen, Kim;Balogh, Adam;Stucki, Gerold;Reginster, Jean-Yves|
|Affiliation:||Austin Health, University of Melbourne, Melbourne, Australia. email@example.com|
|Citation:||Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research; 23(3): 433-8|
|Abstract:||Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia.Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with osteoporosis, is also effective in women with osteopenia.Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral OSteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr.No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96).Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture.|
|Internal ID Number:||17997711|
Aged, 80 and over
Organometallic Compounds.administration & dosage
Osteoporosis, Postmenopausal.complications.drug therapy.epidemiology
Spinal Fractures.epidemiology.etiology.prevention & control
Thiophenes.administration & dosage
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.